1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,060 | 2,155 | 14:07 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:26 | BioInvent International: BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer | 262 | ACCESS Newswire | FDA Fast Track Designation granted for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer.BI-1808 in combination with pembrolizumab demonstrated a 24% confirmed ORR and... ► Artikel lesen | |
| 28.07. | BioInvent International: BioInvent Publication in JECCR: Tailored FcyR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models | 432 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV)Preclinical proof-of-concept data support two distinct FcyR-blockade strategies to enhance cancer antibody therapies and... ► Artikel lesen | |
| BIOINVENT Aktie jetzt für 0€ handeln | |||||
| 17.07. | BioInvent International: BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026 | 403 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 17, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that its... ► Artikel lesen | |
| 11.06. | BioInvent International: BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC | 473 | ACCESS Newswire | BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m. CEST / 5:45 - 8:00 a.m. EDT) in conjunction with EHA 2026 Congress today (virtual event link here)83% ORR across all evaluable... ► Artikel lesen | |
| 11.06. | BioInvent International: BioInvent's TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA in Advanced CTCL | 666 | ACCESS Newswire | BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m. CEST / 5:45 - 8:00 a.m. EDT) in conjunction with EHA 2026 Congress today (virtual event link here)BI-1808 monotherapy achieves... ► Artikel lesen | |
| 01.06. | BioInvent International: BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology | 522 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 1, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it... ► Artikel lesen | |
| 21.05. | BioInvent International: BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA in Advanced Ovarian Cancer at ASCO | 829 | ACCESS Newswire | BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by... ► Artikel lesen | |
| 20.05. | BioInvent International: BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026 | 949 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it... ► Artikel lesen | |
| 12.05. | BioInvent International: BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA in Advanced CTCL | 632 | ACCESS Newswire | 40% objective response rate (ORR) as single agent in heavily pre-treated patients with advanced Cutaneous T-Cell Lymphoma (CTCL)Durable responses observed, including a complete response lasting over... ► Artikel lesen | |
| 12.05. | BioInvent International: BioInvent to Present Clinical Data on FcyRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence in Relapsed/Refractory NHL at EHA 2026 | 932 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory... ► Artikel lesen | |
| 29.04. | BioInvent International: Resolutions at BioInvent's Annual General Meeting 2026 | 398 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2026 / The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect Kate Hermans and Scott Zinober as new... ► Artikel lesen | |
| 29.04. | BioInvent International: BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio | 413 | ACCESS Newswire | Events will feature expert perspectives on BI-1808 in ovarian cancer and T-cell lymphomas, and BI-1206 for the treatment of NHL LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International... ► Artikel lesen | |
| 29.04. | BioInvent International AB: Interim Report January - March 2026 | 512 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV)"During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced... ► Artikel lesen | |
| 21.04. | BioInvent International: BioInvent to Present Data of BI-1808 Plus KEYTRUDA in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting | 463 | ACCESS Newswire | BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when combined... ► Artikel lesen | |
| 31.03. | BioInvent International AB Publishes Annual Report 2025 | 372 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 31, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class... ► Artikel lesen | |
| 26.03. | BioInvent International: BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis | 577 | ACCESS Newswire | BioInvent International (STO:BINV) - Achievement of the milestone triggers a payment of € 1 million LUND, SE / ACCESS Newswire / March 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)... ► Artikel lesen | |
| 24.03. | Notice to Annual General Meeting in BioInvent International AB | 443 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 24, 2026 / BioInvent International (STO:BINV) - The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual... ► Artikel lesen | |
| 26.02. | BioInvent International AB: Year-End Report January 1 - December 31, 2025 | 486 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International (STO:BINV) - "During 2025 we sharpened our clinical focus and resource allocation to accelerate our most advanced assets, BI-1808... ► Artikel lesen | |
| 26.02. | BioInvent International: Invitation to Presentation of BioInvent's Year-End Report 2025 | 332 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report... ► Artikel lesen | |
| 23.02. | BioInvent International: BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting | 654 | ACCESS Newswire | Kate Hermans: Global life sciences executive with 25+ years of leadership across biopharma, commercial strategy, global operations, and value-creation transformations in both public and venture-backed... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,35 | +1,60 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| EVOTEC | 3,510 | +2,27 % | Übernahmekandidaten! Steyr Motors nach 20 %-Sprung! RE Royalties spannend! Und was macht Evotec? | Um 20 % ist die Aktie von Steyr Motors in der vergangenen Woche kurzzeitig explodiert. Grund waren Übernahmespekulationen durch einen Drohnen- und Robotikspezialisten aus den USA. Die Gespräche wurden... ► Artikel lesen | |
| BB BIOTECH | 56,10 | +2,00 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MEDIGENE | 0,008 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 36,865 | +2,01 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| MODERNA | 47,425 | +1,45 % | Ihre wichtigsten Termine: Spannende Zahlen von: Sony, Moderna, AbbVie, Eaton, ExxonMobil, Linde und Puma! | © Foto: picture alliance / CFOTO | CFOTOGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| VALNEVA | 2,291 | +3,20 % | Valneva streicht Jobs - warum die Aktie dennoch steigt | ||
| AMGEN | 351,55 | +0,03 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| EPIGENOMICS | 0,910 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Geschäftszahlen / Halbjahr
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,740 | +0,30 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 177,56 | -0,83 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| BIOFRONTERA | 2,540 | -0,78 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,500 | -0,40 % | Heidelberg Pharma: Der Finanzpuffer öffnet ein Zeitfenster | ||
| ILLUMINA | 168,76 | +0,34 % | Devyser Diagnostics AB: Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy | Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian... ► Artikel lesen | |
| NANOREPRO | 2,000 | +1,01 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
03.08.2026 / 07:15... ► Artikel lesen |
BIOINVENT INTERNATIONAL AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,110 (-5,21 %) liegt der Kurs bei 2,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOINVENT INTERNATIONAL AB finden Sie auf Wallstreet Online.